Deletion of caveolin scaffolding domain alters cancer cell migration

ABSTRACT Caveolin-1 (Cav-1) is an integral membrane protein that plays an important role in proliferative and terminally differentiated cells. As a structural component of Caveolae, Cav-1 interacts with signaling molecules via a caveolin scaffolding domain (CSD) regulating cell signaling. Recent reports have shown that Cav-1 is a negative regulator in tumor metastasis. Therefore, we hypothesize that Cav-1 inhibits cell migration through its CSD. HeLa cells were engineered to overexpress Cav-1 (Cav-1 OE), Cav-1 without a functional CSD (∆CSD), or enhanced green fluorescent protein (EGFP) as a control. HeLa cell migration was suppressed in Cav-1 OE cells while ∆CSD showed increased migration, which corresponded to a decrease in the tight junction protein, zonula occludens (ZO-1). The migration phenotype was confirmed in multiple cancer cell lines. Phosphorylated STAT-3 was decreased in Cav-1 OE cells compared to control and ∆CSD cells; reducing STAT-3 expression alone decreased cell migration. ∆CSD blunted HeLa proliferation by increasing the number of cells in the G2/M phase of the cell cycle. Overexpressing the CSD peptide alone suppressed HeLa cell migration and inhibited pSTAT3. These findings suggest that Cav-1 CSD may be critical in controlling the dynamic phenotype of cancer cells by facilitating the interaction of specific signal transduction pathways, regulating STAT3 and participating in a G2/M checkpoint. Modulating the CSD and targeting specific proteins may offer potential new therapies in the treatment of cancer metastasis.

[1]  H. Patel,et al.  Caveolins as Regulators of Stress Adaptation , 2018, Molecular Pharmacology.

[2]  I. Nabi,et al.  Reciprocal regulation of the Cadherin-11/Stat3 axis by caveolin-1 in mouse fibroblasts and lung carcinoma cells. , 2018, Biochimica et biophysica acta. Molecular cell research.

[3]  Tienian Zhu,et al.  Caveolin-1 Inhibits Proliferation, Migration, and Invasion of Human Colorectal Cancer Cells by Suppressing Phosphorylation of Epidermal Growth Factor Receptor , 2018, Medical science monitor : international medical journal of experimental and clinical research.

[4]  V. Poli,et al.  STAT3 in cancer: A double edged sword. , 2017, Cytokine.

[5]  N. Tardif,et al.  The caveolae dress code: structure and signaling. , 2017, Current opinion in cell biology.

[6]  P. Insel,et al.  Caveolins and cavins in the trafficking, maturation, and degradation of caveolae: implications for cell physiology. , 2017, American journal of physiology. Cell physiology.

[7]  I. Jang,et al.  Cordycepin induces apoptosis by caveolin-1-mediated JNK regulation of Foxo3a in human lung adenocarcinoma , 2017, Oncotarget.

[8]  Ran Wang,et al.  Stellettin B Induces G1 Arrest, Apoptosis and Autophagy in Human Non-small Cell Lung Cancer A549 Cells via Blocking PI3K/Akt/mTOR Pathway , 2016, Scientific Reports.

[9]  M. Camps,et al.  Caveolin interaction governs Kv1.3 lipid raft targeting , 2016, Scientific Reports.

[10]  T. Capiod.  Extracellular Calcium Has Multiple Targets to Control Cell Proliferation. , 2016, Advances in experimental medicine and biology.

[11]  Jason J. Corneveaux,et al.  A Frame-Shift Mutation in CAV1 Is Associated with a Severe Neonatal Progeroid and Lipodystrophy Syndrome , 2015, PloS one.

[12]  K. Griffith,et al.  Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer , 2015, Scientific Reports.

[13]  M. Lindsey,et al.  Caveolin-1 deletion exacerbates cardiac interstitial fibrosis by promoting M2 macrophage activation in mice after myocardial infarction. , 2014, Journal of molecular and cellular cardiology.

[14]  G. Che,et al.  Value of caveolin-1 in cancer progression and prognosis: Emphasis on cancer-associated fibroblasts, human cancer cells and mechanism of caveolin-1 expression (Review) , 2014, Oncology letters.

[15]  R. Lai,et al.  STAT3 in Cancer—Friend or Foe? , 2014, Cancers.

[16]  R. Ortíz,et al.  Caveolin-1 in cell migration and metastasis. , 2014, Current molecular medicine.

[17]  M. Jackson,et al.  The Kinetics of G2 and M Transitions Regulated by B Cyclins , 2013, PloS one.

[18]  D. Massi,et al.  Caveolin-1 as a promoter of tumour spreading: when, how, where and why , 2013, Journal of cellular and molecular medicine.

[19]  P. Chanvorachote,et al.  Caveolin-1 Regulates Endothelial Adhesion of Lung Cancer Cells via Reactive Oxygen Species-Dependent Mechanism , 2013, PloS one.

[20]  N. D’Silva,et al.  Biomarkers of Epithelial-Mesenchymal Transition in Squamous Cell Carcinoma , 2013, Journal of dental research.

[21]  D. Rigden,et al.  Evaluating Caveolin Interactions: Do Proteins Interact with the Caveolin Scaffolding Domain through a Widespread Aromatic Residue-Rich Motif? , 2012, PloS one.

[22]  G. Riggins,et al.  Caveolin-1, caveolae, and glioblastoma. , 2012, Neuro-oncology.

[23]  H. Urra,et al.  Caveolin-1-Enhanced Motility and Focal Adhesion Turnover Require Tyrosine-14 but Not Accumulation to the Rear in Metastatic Cancer Cells , 2012, PloS one.

[24]  I. Ng,et al.  Caveolin‐1 overexpression is associated with hepatocellular carcinoma tumourigenesis and metastasis , 2012, The Journal of pathology.

[25]  Matthew N. Srnec,et al.  Structural Characterization of the Caveolin Scaffolding Domain in Association with Cholesterol-Rich Membranes , 2011, Biochemistry.

[26]  Yu-Chun Lin,et al.  Interaction abolishment between mutant caveolin-1(Δ62-100) and ABCA1 reduces HDL-mediated cellular cholesterol efflux. , 2011, Biochemical and biophysical research communications.

[27]  J. Guan,et al.  Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. , 2011, Advanced drug delivery reviews.

[28]  K. Aldape,et al.  Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by stat3 inhibition. , 2011, Cancer research.

[29]  H. Althaus,et al.  Effect of Cavtratin, a Caveolin-1 Scaffolding Domain Peptide, on Oligodendroglial Signaling Cascades , 2011, Cellular and Molecular Neurobiology.

[30]  J. Balsinde,et al.  Caveolin-1 Deficiency Causes Cholesterol-Dependent Mitochondrial Dysfunction and Apoptotic Susceptibility , 2011, Current Biology.

[31]  M. Dowsett,et al.  The role of caveolin-1 in human breast cancer , 2011, Breast Cancer Research and Treatment.

[32]  Liying Wang,et al.  Regulation of Lung Cancer Cell Migration and Invasion by Reactive Oxygen Species and Caveolin-1* , 2010, The Journal of Biological Chemistry.

[33]  J. Reis-Filho,et al.  Caveolin-1 P132L mutation in human cancers: 1 CAVeat to be voiced. , 2010, The Journal of molecular diagnostics : JMD.

[34]  E. Grande,et al.  The dual kinase complex FAK-Src as a promising therapeutic target in cancer , 2010, OncoTargets and therapy.

[35]  Hong Zhu,et al.  Caveolin-1 regulating the invasion and expression of matrix metalloproteinase (MMPs) in pancreatic carcinoma cells. , 2010, The Journal of surgical research.

[36]  H. Althaus,et al.  Mutual effects of caveolin and nerve growth factor signaling in pig oligodendrocytes , 2009, Journal of neuroscience research.

[37]  Brij B. Singh,et al.  Activation of TRPC1 by STIM1 in ER-PM microdomains involves release of the channel from its scaffold caveolin-1 , 2009, Proceedings of the National Academy of Sciences.

[38]  S. Hehlgans,et al.  Caveolin-1 mediated radioresistance of 3D grown pancreatic cancer cells. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[39]  Paul A Insel,et al.  Lipid rafts and caveolae and their role in compartmentation of redox signaling. , 2009, Antioxidants & redox signaling.

[40]  A. Malik,et al.  Caveolin-1 scaffold domain interacts with TRPC1 and IP3R3 to regulate Ca2+ store release-induced Ca2+ entry in endothelial cells. , 2009, American journal of physiology. Cell physiology.

[41]  Per E Andrén,et al.  Use of surface plasmon resonance coupled with mass spectrometry reveals an interaction between the voltage-gated sodium channel type X alpha-subunit and caveolin-1. , 2008, Journal of proteome research.

[42]  M. Ebert,et al.  Caveats of caveolin-1 in cancer progression. , 2008, Cancer letters.

[43]  J. Hancock,et al.  Caveolin Regulates Endocytosis of the Muscle Repair Protein, Dysferlin* , 2008, Journal of Biological Chemistry.

[44]  P. Insel,et al.  Caveolae as organizers of pharmacologically relevant signal transduction molecules. , 2008, Annual review of pharmacology and toxicology.

[45]  M. Shatz,et al.  Caveolin-1: A tumor-promoting role in human cancer , 2008, International journal of radiation biology.

[46]  P. Insel,et al.  G-protein-coupled receptor-signaling components in membrane raft and caveolae microdomains. , 2008, Handbook of experimental pharmacology.

[47]  A. Tomassetti,et al.  Binding of nuclear caveolin-1 to promoter elements of growth-associated genes in ovarian carcinoma cells. , 2007, Experimental cell research.

[48]  J. Lin,et al.  Stat3 activation in human endometrial and cervical cancers , 2007, British Journal of Cancer.

[49]  M. Lisanti,et al.  Overexpression of Caveolin-1 Inhibits Endothelial Cell Proliferation by Arresting the Cell Cycle at G0/G1 Phase , 2007, Cell cycle.

[50]  A. Malik,et al.  Caveolin-1 Regulates Store-Operated Ca2+ Influx by Binding of Its Scaffolding Domain to Transient Receptor Potential Channel-1 in Endothelial Cells , 2006, Molecular Pharmacology.

[51]  F. Sotgia,et al.  SOCS proteins and caveolin-1 as negative regulators of endocrine signaling , 2006, Trends in Endocrinology & Metabolism.

[52]  D. Rodriguez,et al.  Caveolin-1 controls cell proliferation and cell death by suppressing expression of the inhibitor of apoptosis protein survivin , 2006, Journal of Cell Science.

[53]  P. Insel,et al.  G-protein-coupled Receptor Signaling Components Localize in Both Sarcolemmal and Intracellular Caveolin-3-associated Microdomains in Adult Cardiac Myocytes* , 2005, Journal of Biological Chemistry.

[54]  L. Pelkmans,et al.  Assembly and trafficking of caveolar domains in the cell , 2005, The Journal of cell biology.

[55]  E. Kochs,et al.  Long‐term effects of hypothermia on neuronal cell death and the concentration of apoptotic proteins after incomplete cerebral ischemia and reperfusion in rats , 2005, Acta anaesthesiologica Scandinavica.

[56]  M. I. Ramirez,et al.  Transcription of the Caveolin-1 Gene Is Differentially Regulated in Lung Type I Epithelial and Endothelial Cell Lines , 2004, Journal of Biological Chemistry.

[57]  M. Lisanti,et al.  The Caveolin genes: from cell biology to medicine , 2004, Annals of medicine.

[58]  R. Parton,et al.  Dynamic and regulated association of caveolin with lipid bodies: modulation of lipid body motility and function by a dominant negative mutant. , 2003, Molecular biology of the cell.

[59]  T. Thompson,et al.  Caveolin-1 Maintains Activated Akt in Prostate CancerCells through Scaffolding Domain Binding Site Interactions with andInhibition of Serine/Threonine Protein Phosphatases PP1 andPP2A , 2003, Molecular and Cellular Biology.

[60]  O. Bachs,et al.  The SET Protein Regulates G2/M Transition by Modulating Cyclin B-Cyclin-dependent Kinase 1 Activity* , 2003, The Journal of Biological Chemistry.

[61]  Richard G. W. Anderson,et al.  Multiple Functions of Caveolin-1* , 2002, The Journal of Biological Chemistry.

[62]  S. Woodman,et al.  Caveolae: From Cell Biology to Animal Physiology , 2002, Pharmacological Reviews.

[63]  James K. Chen,et al.  The checkpoint protein Chfr is a ligase that ubiquitinates Plk1 and inhibits Cdc2 at the G2 to M transition , 2002, The Journal of cell biology.

[64]  L. Leyton,et al.  Caveolae and caveolae-like membrane domains in cellular signaling and disease: identification of downstream targets for the tumor suppressor protein caveolin-1. , 2002, Biological research.

[65]  M. Lisanti,et al.  Two distinct caveolin-1 domains mediate the functional interaction of caveolin-1 with protein kinase A. , 2001, American journal of physiology. Cell physiology.

[66]  M. Lisanti,et al.  Caveolin-1 expression negatively regulates cell cycle progression by inducing G(0)/G(1) arrest via a p53/p21(WAF1/Cip1)-dependent mechanism. , 2001, Molecular biology of the cell.

[67]  R. Medema,et al.  Checking out the G(2)/M transition. , 2001, Biochimica et biophysica acta.

[68]  R. D. Rudic,et al.  In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation , 2000, Nature Medicine.

[69]  J. Srinivasan,et al.  Involvement of caveolin-1 in meiotic cell-cycle progression in Caenorhabditis elegans , 1999, Nature Cell Biology.

[70]  V. J. Venema,et al.  VEGF induces nuclear translocation of Flk-1/KDR, endothelial nitric oxide synthase, and caveolin-1 in vascular endothelial cells. , 1999, Biochemical and biophysical research communications.

[71]  H. Koizumi,et al.  Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analyses. , 1997, The American journal of pathology.

[72]  Richard G. W. Anderson,et al.  A Role for Caveolin in Transport of Cholesterol from Endoplasmic Reticulum to Plasma Membrane* , 1996, The Journal of Biological Chemistry.